Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 0.9078 USD 0.81% Market Closed
Market Cap: 167.5m USD
Have any thoughts about
Nektar Therapeutics?
Write Note

Nektar Therapeutics
Accumulated Depreciation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nektar Therapeutics
Accumulated Depreciation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accumulated Depreciation CAGR 3Y CAGR 5Y CAGR 10Y
Nektar Therapeutics
NASDAQ:NKTR
Accumulated Depreciation
-$15.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Accumulated Depreciation
-$28.8B
CAGR 3-Years
0%
CAGR 5-Years
-2%
CAGR 10-Years
-3%
Bristol-Myers Squibb Co
NYSE:BMY
Accumulated Depreciation
-$4.8B
CAGR 3-Years
-7%
CAGR 5-Years
-4%
CAGR 10-Years
-1%
Pfizer Inc
NYSE:PFE
Accumulated Depreciation
-$16.6B
CAGR 3-Years
-2%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Accumulated Depreciation
-$19.1B
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
0%
Eli Lilly and Co
NYSE:LLY
Accumulated Depreciation
-$11.8B
CAGR 3-Years
-6%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
No Stocks Found

Nektar Therapeutics
Glance View

Market Cap
167.5m USD
Industry
Pharmaceuticals

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

NKTR Intrinsic Value
0.6997 USD
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Nektar Therapeutics's Accumulated Depreciation?
Accumulated Depreciation
-15.7m USD

Based on the financial report for Sep 30, 2024, Nektar Therapeutics's Accumulated Depreciation amounts to -15.7m USD.

What is Nektar Therapeutics's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 1Y
82%

Over the last year, the Accumulated Depreciation growth was 82%.

Back to Top